Bicycle Therapeutics PLC (BCYC) is not a strong buy for a beginner, long-term investor at this time. Despite positive revenue growth and improving financial metrics, the stock shows bearish technical indicators, insider selling, and lacks positive trading sentiment or strong catalysts. It is better to wait for clearer signals or improved sentiment before considering investment.

Technical Analysis

The MACD histogram is positive and expanding, indicating a potential bullish momentum. However, the RSI is neutral at 53.645, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key resistance levels (R1: 5.79, R2: 5.995) and close to its pivot point (5.46), suggesting limited upward momentum.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Net income and EPS also showed improvements YoY, signaling progress in financial performance.

Neutral/Negative Catalysts

Insiders are selling heavily, with a 253.11% increase in selling activity over the last month. No recent news or event-driven catalysts. The stock lacks strong trading sentiment, and hedge funds are neutral.

Financial Performance

In Q3 2025, revenue increased by 338.49% YoY to $11,734,000. Net income improved by 16.33% YoY to -$59,100,000. EPS increased by 14.86% YoY to -0.85. Gross margin remained at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

2 Analyst Rating

Wall Street analysts forecast BCYC stock price to rise

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 5.730

Low

Averages

High

Current: 5.730

Low

Averages

High

Truist

Hold

initiated

$10

AI Analysis

2025-11-24

Reason

Truist

Price Target

$10

AI Analysis

2025-11-24

initiated

Hold

Reason

Truist initiated coverage of Bicycle Therapeutics with a Hold rating and $10 price target. The time to market and ultimate market potential remains uncertain for Zele, pending further visibility from the Phase 2/3 Duravelo-2 trial, particularly as Padcev continues to entrench as a widely adopted standard of care, the analyst tells investors in a research note. Truist adds that it sees broader value from Bicycle's pipeline, including BT5528, and the radiopharma franchise, though these programs remain early in development and are unlikely to yield meaningful near-term contribution.

RBC Capital

Leonid Timashev

Outperform -> Sector Perform

downgrade

$27 -> $11

2025-10-31

Reason

RBC Capital

Leonid Timashev

Price Target

$27 -> $11

2025-10-31

downgrade

Outperform -> Sector Perform

Reason

RBC Capital analyst Leonid Timashev last night downgraded Bicycle Therapeutics to Sector Perform from Outperform with a price target of $11, down from $27, following the Q3 report. The company's pipeline programs are taking more time to reach inflection points, the analyst tells investors in a research note. RBC thinks Bicycle's near-term updates may not provide substantial enough data to de-risk its programs and drive share upside. As such, the firm moves to the sidelines pending greater visibility into the path forward for zelenectide and BT5528.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BCYC

Unlock Now

BCYC Should I Buy

BCYC Should I Buy

Should You Buy Bicycle Therapeutics PLC (BCYC) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch